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ABSTRACT
Background: Technological developments have enabled the ex-
pansion of percutaneous coronary intervention (PCI) indications 
for more challenging clinical and angiographic scenarios. Our 
objective was to evaluate the results of PCI in two different 
periods in the past 6 years. Methods: This was a multicenter 
registry including 6,288 consecutive patients treated by PCI, 
who were divided according to different treatment periods: 
2006 to 2008 (P1; n = 1,779) and 2009 to 2012 (P2; n = 
4,509). We intended to compare the rates of in-hospital major 
adverse cardiac and cerebrovascular events (MACCE) and identify 
their predictors. Results: P2 patients were younger and had a 
higher prevalence of smoking and diabetes. These patients had 
a greater rate of multivessel, thrombotic and bifurcation lesions. 
The number of diseased vessels per patient was higher in the 
P2 Group, as well as the number of stents per patient, and 
the use of drug-eluting stents. MACCE was more frequent in 
P2 patients (2.5% vs. 3.5%; P = 0.04), due to periprocedural 
myocardial infarction (1.7% vs. 2.6%; P = 0.05), and there were 
no differences in terms of death (1.0% vs. 1.0%; P = 0.87), 
stroke (0.2% vs. 0.1%; P = 0.47) or emergency coronary artery 
bypass grafting (0.1% vs. 0; P = 0.68). Age (odds ratio – OR 
– 1.02; 95% confidence interval – CI 95% – 1.00-1.05; P = 
0.04) and Killip III/IV (OR = 6.0, 95% CI; 3.3-10.9; P < 0.01) 
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RESUMO
Mudanças no Perfil Populacional e Resultados 
da Intervenção Coronária Percutânea do Registro 
Angiocardio
Introdução: A evolução tecnológica tem permitido ampliar 
a indicação da intervenção coronária percutânea (ICP) para 
cenários clínicos e angiográficos mais desafiadores. Nosso 
objetivo foi avaliar os resultados da ICP em dois diferentes 
períodos, nos últimos 6 anos. Métodos: Registro multicêntrico 
no qual 6.288 pacientes consecutivos tratados por ICP foram 
divididos por períodos de tratamento: 2006 a 2008 (P1; n = 
1.779) e 2009 a 2012 (P2; n = 4.509). Buscamos comparar as 
taxas de eventos cardíacos e cerebrovasculares adversos maiores 
(ECCAM) hospitalares e identificar seus preditores. Resultados: 
Pacientes do Grupo P2 mostraram ser mais jovens, com maior 
prevalência de tabagismo e diabetes. Esses pacientes mostr-
aram maior acometimento de múltiplos vasos, maior número 
de lesões trombóticas e lesões em bifurcações. A relação de 
vasos tratados/paciente foi maior no Grupo P2, assim como a 
relação stent/paciente e a utilização de stents farmacológicos. 
ECCAM foi mais frequente no Grupo P2 (2,5% vs. 3,5%; P = 
0,04), às custas do infarto periprocedimento (1,7% vs. 2,6%; 
P = 0,05), não havendo diferenças quanto a óbito (1,0% vs. 
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were the variables that best explained the presence of MACCE. 
Conclusions: In this large cohort, substancial changes occurred 
in the characteristics of patients treated by PCI in the last 6 
years. This more complex scenario was associated to a slight 
increase of periprocedural myocardial infarctions, but not to 
other in-hospital clinical adverse events.
 
 
 
 
DESCRIPTORS: Coronary artery disease. Myocardial infarction. 
Percutaneous coronary intervention. Health profile. Treatment 
outcome. Registries.
included 1,779 patients; the second period (P2) was 
from 2009 to 2012 and included 4,509 patients. The 
primary objective was to compare the rates of major 
adverse cardiac and cerebrovascular events (MACCE), 
comprising in-hospital death, periprocedural myocardial 
infarction, stroke, and emergency coronary artery bypass 
graft surgery (CABG) at the time of hospital discharge 
between the determined periods.
Procedure
The interventions were almost always performed 
via femoral access; the radial approach was used as 
an option in a few cases. The choice of technique and 
material used during the procedure were at the sur-
geon’s discretion, as was the assessmentof the need for 
glycoprotein IIb/IIIa inhibitors. Unfractionated heparin 
was used in the start of procedure at a dose of 70 U/kg 
to 100 U/kg, except in patients who already used low-
molecular-weight heparin. 
All patients received antiplatelet therapy combined 
with acetylsalicylic acid (ASA), at loading doses of 300 
mg and maintenance dose of 100 mg/day to 200 mg/
day, and clopidogrel at loading doses of 300 mg to 
600 mg and maintenance dose of 75 mg/day. Femoral 
sheaths were removed fourhours after the start of hepa-
rinization. Radials sheaths were removed immediately 
after the procedure.
Angiographic analysis and definitions 
Analyses were performed on at least two or-
thogonal projections by experienced professionals, 
using digital quantitative angiography. This study used 
the angiographic criteria found in National Center 
of Cardiovascular Interventions (Central Nacional de 
Intervenções Cardiovasculares – CENIC) database of 
Brazilian Society of Hemodynamics and Interventional 
Cardiology (Sociedade Brasileira de Hemodinâmica e 
Cardiologia Intervencionista – SBHCI). The type of le-
sion was classified according to the criteria of American 
College of Cardiology and American Heart Association 
1,0%; P = 0,87), acidente vascular cerebral (0,2% vs. 0,1%; P 
= 0,47) ou cirurgia de revascularização de emergência (0,1% 
vs. 0; P = 0,68). Idade (odds ratio – OR – de 1,02; intervalo 
de confiança de 95% – IC 95% – de 1,00-1,05; P = 0,04) e 
Killip III/IV (OR = 6,03, IC 95%; 3,39-10,90; P < 0,01) foram 
as variáveis que melhor explicaram a presença de ECCAM. 
Conclusões: Nessa grande coorte, mudanças substanciais 
ocorreram nas características de pacientes tratados por ICP 
nos últimos 6 anos. O cenário mais complexo associou-se 
a discreto aumento de infartos periprocedimento, mas não a 
outros eventos adversos clínicos hospitalares.
DESCRITORES: Doença da artéria coronariana. Infarto do 
miocárdio. Intervenção coronária percutânea. Perfil de saúde.
Resultado de tratamento. Registros.
INTRODUCTION
Since the performance of the first balloon-catheter 
angioplasty, in 1977, at Andreas Gruentzigat Zurich 
University,1 percutaneous coronary intervention (PCI) 
has advanced significantly. Over the past 20 years, 
the development of materials, image acquisition, and 
technical improvement has allowed excellent results, 
establishing the percutaneous intervention as the first-
line treatment in acute myocardial infarction (AMI) with 
ST-segment elevation,2,3 which can be indicated for all 
clinical forms and anatomical variations of patients 
with coronary artery disease (CAD).4-6
The advances in interventional cardiology have 
promoted a change in the profile of patients undergo-
ing percutaneous therapy. Currently, PCI is increasingly 
used in patients with more comorbidities and more 
complex CAD.4,5,7
The change in the clinical profile of patients over 
the years can influence the outcomes after PCI in 
randomised clinical trials, as well as in registries.4,8 
The aim of the present study was to verify the evolu-
tionary differences of the clinical, angiographic, and 
procedural profile, as well as in-hospital outcomes of 
patients undergoing PCI in the last six years of the 
Angiocardio Registry.
METHODS
Population
From August 2006 to October 2012, 6,288 consecu-
tive patients underwent PCI at the centers that constitute 
the Angiocardio Registry (Hospital Bandeirantes, Rede 
D’Or São Luiz Analia Franco and Hospital Leforte, in 
São Paulo, SP, Brazil; Hospital Vera Cruz, in Campinas, 
SP, Brazil; and Hospital Regional do Vale do Paraíba, 
in Taubaté, SP, Brazil). Data were prospectively col-
lected and stored in a computerized database available 
through the Internet in all centres participating in the 
registry. The analysis was performed in two periods: 
the first period (P1) was from 2006 to 2008 and 
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(ACC/AHA).9 The Thrombolysis in Myocardial Infarction 
(TIMI)10 classification was used to determine pre- and 
post-procedural coronary flow. Procedural success was 
defined as achievement of angiographic success (residual 
stenosis < 30 % with TIMI 3 flow) and absence of 
MACCE, comprising death, periprocedural myocardial 
infarction, stroke, and emergency CABG.11
Deaths from any cause were recorded and cardiac 
mortality was defined as that resulting from cardiogenic 
shock, heart failure, AMI, cardiac rupture, arrhythmia, 
or sudden death during hospital stay. Periprocedural 
infarction was defined by the reappearance of angina 
symptoms, with the presence of electrocardiographic 
alterations (new ST-segment elevation or new Q waves) 
and/or angiographic evidence oftarget vessel occlusion. 
Emergency CABG was considered when performed 
immediately after PCI.
Statistical analysis
The data stored in the Oracle-based database were 
plotted in Excel spreadsheets and analyzed using SPSS 
version 15.0. The continuous variables were expressed 
as means and standard deviations, and categorical 
variables were expressed as absolute numbers and 
percentiles. Associations between continuous variables 
were evaluated using the ANOVA model. The associa-
tions between categorical variables were evaluated by 
the chi-squared test, Fisher’s exact test, or likelihood 
ratios, when appropriate. Significance level was set at 
P < 0.05. Single and multiple logistic regression models 
were applied to identify predictors of MACCE.
RESULTS
The clinical characteristics are shown in Table 1. 
The group treated in the more recent period (P2) was 
found to be, on average, two years younger, with higher 
prevalence of smokers and diabetics, and lower preva-
lence of arterial hypertension, dyslipidemia, and prior 
CABG. It also showed a greater number of asymptomatic 
patients or those with AMI with ST-segment elevation. 
From the angiography point of view, patients in the 
P2 group had a more complex profile, with a higher 
TABLE 1  
Clinical characteristics 
Characteristics
P1  
(n = 1,779)
P2  
(n = 4,509) P
Age, years 63.1 ± 11.9 61.3 ± 11.8 < 0.01
Male gender, n (%) 1,187 (66.7) 3,111 (69.0) 0.09
Smoking, n (%) 360 (20.2) 1,203 (26,7) < 0.01
Arterial hypertension, n (%) 1,378 (77.5) 3,288 (72.9) < 0.01
Dyslipidemia, n (%) 704 (39.6) 1,537 (34.1) < 0.01
Diabetes, n (%) 499 (28.0) 1,397 (31.0) 0.02
Prior myocardial infarction, n (%) 309 (17.4) 710 (15.7) 0.12
Prior coronary artery bypass graft surgery, n (%) 214 (12.0) 451 (10.0) 0.22
Prior stroke, n (%) 46 (2.6) 145 (3.2) 0.22
Prior percutaneous coronary intervention, n (%) 347 (19.5) 955 (21.2) 0.15
Chronic renal failure, n (%) 43 (2.4) 119 (2.6) 0.68
Clinical status, n (%) < 0.01
Asymptomatic 454 (25.5) 1,339 (29.7)
Stable angina 541 (30.4) 1,022 (22,7)
Ischemic equivalent 116 (6.5) 296 (6.6)
Acute coronary syndrome 307 (17.3) 631 (14.0)
Acute myocardial infarction 361 (20.3) 1,221 (27.1)
Killip, n (%) 0.52
I 157 (76.6) 465 (74.4)
II 27 (13.2) 89 (14.2)
III 3 (1.5) 21 (3.4)
IV 18 (8.8) 50 (8.0)
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rate of multivessel involvement, and a higher number 
of thrombotic and bifurcation lesions (Table 2). 
Regarding the procedural characteristics (Table 3), 
the ratio of treated vessels per patient was higher in 
the P2 group (1.3 ± 0.6 vs. 1.4 ± 0.7; P < 0.01), as 
well as the stent/patient ratio (1.2 ± 0.6 vs. 1.3 ± 0.7; 
P = 0.02) and the use of drug-eluting stents (10.9% 
vs. 25.1%; P < 0.01). With respect to the dimensions 
of the implanted prostheses, they had greater diameter 
and length in the P2 group (2.94 ± 0.45 mm vs. 2.98 ± 
0.50 mm; P < 0.01 and 17.9 ± 6.7 mm vs. 18.9 ± 7.1 
mm; P < 0.01, respectively). Direct stenting was less 
commonly performed (52.3 % vs. 35.7%; P  <  0.01), 
and thrombus aspiration was more used in P2 group 
(0.8 % vs. 3.6%; P <  0.01).
Table 4 shows the clinical outcome in the hos-
pital phase. It was observed that MACCE was more 
frequent in the P2 group (2.5% vs. 3.5%; P = 0.04) at 
the expense of periprocedural AMI (1.7 % vs. 2.6%; 
P = 0.05), with no difference between groups regarding 
in-hospital deaths (1.0 % vs. 1.0%; P = 0.87), stroke 
(0.2 % vs. 0.1%; P  =  0.47), or emergency CABG (0.1 
% vs. 0%; P = 0.68).
In the univariate analysis, the variables age; Killip 
functional class III/IV; multivessel involvement; lesions 
type B2/C; long, calcified or thrombotic lesions; occlusive 
lesions; TIMI flow 0/1 pre-PCI; presence of collateral 
circulation; primary PCI; and use of glycoprotein IIb/
IIIa inhibitors and thrombus aspiration showed a sig-
nificant association with the occurrence of MACCE. In 
the multivariate analysis, age (odds ratio [OR]: 1.02; 95 
% confidence interval [95% CI]: 1.00-1.05; P = 0.04) 
and Killip class III/IV (OR: 6.0; 95% CI; 3.3-10.9; P < 
0.01) were the variables that best explained the pres-
ence of in-hospital MACCE (Table 5).
DISCUSSION
The observation of this daily clinical practice and 
the literature data have shown changes in the profile 
of patients treated with PCI over the years, resulting 
TABLE 2  
Angiographic Characteristics
Characteristics
P1 
(n = 1,779/ 2,311 
vessels/2,501 lesions)
P2 
(n = 4,509/ 6,402 
vessels/6,700 lesions) P
Coronary disease extension, n (%) < 0.01
One-vessel disease 1,311 (73.7) 3,182 (70.6)
Two-vessel disease 402 (22.6) 1,067 923.7)
Three-vessel disease 66 (3.7) 260 95.8)
Treated vessels, n (%) 0.28
Right coronary artery 701 (30.3) 1,773 (29.3)
Left Circumflex artery 601 (26.0) 1,541 (25.5)
Left anterior descending artery 903 (39.1) 2,478 (41.0)
Grafts 94 (4.1) 207 (3.4)
Left main coronary artery 12 (0.5) 43 (0.7)
Type B2/C lesions, n (%) 1,260 (58.2) 3,344 (55.9) 0.07
Calcified lesions, n (%) 332 (13.3) 908 (13.6) 0.77
Thrombotic lesions, n (%) 186 (7.5) 640 (9.6) < 0.01
Long lesions, n (%) 288 (11.6) 845 (12.6) 0.17
Bifurcations, n (%) 157 (6.3) 613 (9.2) < 0.01
Total occlusions, n (%) 328 (13.2) 895 (13.4) 0.80
Left ventricular dysfunction, n (%) 210 (43.2) 192 (40.3) 0.39
TIMI pre, n (%) 0.99
0/1 384 (15.4) 1,028 (15.4)
2/3 2,106 (84.6) 5,653 (84.6)
Collateral circulation, 346 (13.8) 950 (14.2)
TIMI = Thrombolysis in Myocardial Infarction.
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TABLE 3  
Characteristics of the procedures
Characteristics
P1 
(n = 1,799/2331 vessels / 2,501 
vessels)
P2 
(n = 4,509/6,042 vessels/ 
6,700 vessels) P
Treated vessels/patient 1.3 ± 0.6 1.4 ± 0.7 < 0.01
Stent use, n (%) 1,681 (94.5) 4,271 (94.7) 0.76
Stent/patient ratio, n (%) 1.2 ± 0.6 1.3 ± 0.7 0.02
Drug-eluting stents, n (%) 229 (10.9) 1,383 (25.1) < 0.01
Direct stenting technique, n (%) 1,097 (52.3) 1,966 (35.7) < 0.01
Stent diameter, mm 2.94 ± 0.45 2.98 ± 0.50 0.01
Stent length, mm 17.9 ± 6.7 18.9 ± 7.1 < 0.01
Primary PCI, n (%) 140 (7.9) 459 (10.2) < 0.01
Rescue PCI, n (%) 65 (3.7) 137 (3.0) 0.24
Glycoprotein IIb/IIIa inhibitors, n (%) 114 (6.4) 339 (7.5) 0.14
Thrombus aspiration, n (%) 14 (0.8) 154 (3.6) < 0.01
TIMI post, n (%) 0.30
0/1 55 (2.3) 123 (1.9)
2/3 2,307 (97.7) 6,203 (98.1)
Degree of stenosis, n (%) 0.02
Pre 83.6 ± 12.3 82.9 ± 13.1 0.02
Post 4.8 ± 17.5 3.1 ± 15.2 < 0.01
Procedural success, n (%) 1,704 (95.8) 4,299 (95.3) 0.49
ICP = percutaneous coronary intervention PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
TABLE 4  
Clinical outcomes during hospitalisation
Outcome
P1  
(n = 1,799)
P2  
(n = 4,509) P
MACCE, n (%) 45 (2.5) 160 (3.5) 0.04
In-hospital death, n (%) 17 (1.0) 47 (1.0) 0.87
AMI post, n (%) 31 (1.7) 117 (2.6) 0.05
Stroke, n (%) 3 (0.2) 3 (0.1) 0.47
Emergency CABG, n (%) 2 (0.1) 2 (0.04) 0.68
MACCE = major adverse cardiac and cerebrovascular events, 
AMI = acute myocardial infarction
TABLE 5  
Independent predictors of major adverse cardiac and 
cerebrovascular events
Factors OR 95% CI P
Age, years 1.02 1.00; 1.05 0.04
Killip (III-IV) 6.03 3.29; 10,90 < 0.01
OR = odds ratio; 95% CI = 95 % confidence interval.
from technological developments of the procedure, 
and alterations in CAD epidemiology and risk factors. 
These changes have been very significant in registries 
that evaluate long periods, especially when including 
comparisons of intervention results before and after 
the introduction of stents, or even before and after the 
availability of drug-eluting stents. This contemporary 
registry demonstrated that differences might be found 
in a shorter period of time, as technological changes 
increase by geometric progression, which promotes 
the treatment of more clinically and angiographically 
complex patients.
In this study, patients from the most recent period 
(P2) were younger and showed a higher prevalence 
of smokers and diabetics. The occurrence of coronary 
heart disease among young people has increased over 
the years. The French registry FAST AMI showed a sig-
nificant increase of AMI in young individuals in the last 
15 years, in both males and (especially) in females.12 
One of the observations that could explain this fact 
was the significant increase of obesity and smoking 
(as in the present registry). Previous Brazilian data 
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also show this trend, as is the case of the Risk Factors 
Associated with Myocardial Infarction in Brazil (AFIR-
MAR) study,13 which indicated the increase of AMI in 
younger patients and smokers. The presence of a higher 
number of diabetic patients in the second study period 
has an additional association with the increased supply 
of pharmacological stents in this period, providing a 
more effective approach with lower rates of restenosis 
in this population.14
The implementation of chest pain protocols in 
hospitals participating in the registry, with primary PCI 
availability 24 hours a day, may explain the growing 
number of this type of PCI in the present registry. Re-
garding the care of AMI, the rate of use of glycoprotein 
IIb/IIIa inhibitors remained stable and low (6.4 % to 7.5 
%) during the study period, which has been a trend in 
literature since the advent of clopidogrel, new antiag-
gregants, and the use of thrombus aspiration catheters12 
The more frequent use of aspiration catheters in the 
second period group coincides with the publication, 
in 2008, of the TAPAS trial results, which showed the 
superiority of thrombus aspiration technique to treat AMI 
with ST-segment elevation, reducing cardiac mortality 
combined with non fatal reinfarction within one year.15,16 
The continuous improvement of the material used 
in the PCI, such as balloons and stents of better navi-
gability and smaller calibre, guide wires with different 
characteristics of flexibility and stiffness, and drug-eluting 
stents, for instance, has increased the possibilities of 
using of the percutaneous technique in patients with 
greater angiographic complexity. This was also observed 
in the present study, with patients from P2 showing 
more severe coronary disease, such as multivessel in-
volvement, thrombotic lesions, and diffuse (> 20 mm) 
and bifurcation lesions, requiring the use of longer and 
pharmacological stents. This finding was also described 
by Cardoso et al.17 in an observational study based on 
the CENIC database. 
While the technological advancement of materials 
and adjunct medications used in PCI aim to achieve 
better results, with high success rates and low rate of 
complications, this registry observed a tendency of slight 
increase in MACCE in recent years, probably due to 
the increasing complexity of patients undergoing PCI.
Study limitations
The limitations of the present study were the 
retrospective analysis of data, its performance by a 
single group of interventionists, and the lack of long-
term follow-up.
CONCLUSIONS
In this large cohort, there were substantial changes 
in clinical, angiographic, and procedural characteristics 
of patients treated by PCI from 2006 to 2012. The more 
complex scenario was associated with a slight increase 
in periprocedural infarctions, but not to other adverse 
in-hospital clinical events.
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